Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Basic advances and new avenues in therapy of spinal cord injury
Bruce H. Dobkin
, Leif A. Havton
Research output
:
Contribution to journal
›
Review article
›
peer-review
105
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Basic advances and new avenues in therapy of spinal cord injury'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Activity-dependent Plasticity
100%
Acute Myelopathy
100%
Animal Models of Injury
100%
Axon
100%
Bench to Bedside
100%
Biological Therapy
100%
Bladder Management
100%
Bowel Control
100%
Cell Interaction
100%
Chronic Myelitis
100%
Circuitry
100%
Clinical Targets
100%
Clinical Trials
100%
Delivery System
100%
Dysautonomia
100%
Functional Applications
100%
Gene Expression
100%
Human Condition
100%
Motor Neuron
100%
Motor Unit
100%
Neural Repair
100%
Neurobiology
100%
Neuronal Cells
100%
Neuroprotective
100%
Neurorestorative
100%
Preclinical Animal Models
100%
Rehabilitation Therapy
100%
Repair Strategy
100%
Sensorimotor System
100%
Sensory Neurons
100%
Spinal Cord
100%
Spinal Cord Injury
100%
Spinal Cord Injury Rehabilitation
100%
Spinal Cord Lesion
100%
Temporal Window
100%
Traumatic Spinal Cord Injury
100%
Window of Opportunity
100%
Medicine and Dentistry
Axon
50%
Biological Therapy
50%
Bladder
50%
Cell Interaction
50%
Clinical Trial
50%
Drive
50%
Dysautonomia
50%
Gene Expression
50%
Motor Unit
50%
Nervous System Cell
50%
Neural Pathway
50%
Neuroprotective Agent
50%
Rehabilitation (Therapeutic Procedure)
50%
Spinal Cord Disease
50%
Spinal Cord Injury
100%
Spinal Cord Lesion
50%
Traumatic Spinal Cord Injury
50%
Neuroscience
Axon
50%
Cell Interaction
50%
Dysautonomia
50%
Gene Expression
50%
Motor Unit
50%
Nervous System Cell
50%
Neural Pathway
50%
Neuroprotective Agent
50%
Neuroscience
50%
Spinal Cord Disease
50%
Spinal Cord Injury
100%
Traumatic Spinal Cord Injury
50%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
33%
Dysautonomia
33%
Neuroprotective Agent
33%
Spinal Cord Disease
33%
Spinal Cord Injury
100%
Spinal Cord Lesion
33%